In today ‘ s medical field, there has been significant progress in the treatment of oesophagus cancer, with increasingly diverse treatments, including surgery, treatment, chemotherapy and comprehensive treatment. The treatment of early oesophagus cancer is largely dependent on surgical removal, which is a direct and effective method of removing the tumor and its potentially affected tissues through surgical operations, thus significantly reducing the risk of relapse. However, for patients who have unfortunately been diagnosed as partially late in life or who are no longer able to undergo surgical treatment, the main weapon in their fight against cancer is medical and chemotherapy. Through precise radiation exposures, therapeutics can provide local control of tumours, although this approach may have some side effects, such as radio-eateritis, but its effectiveness in controlling tumour proliferation cannot be overlooked. As a full-body treatment, chemotherapy is usually used for para-surgery to reduce the risk of relapse or for extended survival for late patients. Integrated treatment combines different treatment methods, such as surgery, treatment and chemotherapy, in a multipronged approach that seeks to achieve optimal treatment.
In terms of treatment, surgical treatment usually includes oesophagus and lymphomy scavengers aimed at the complete removal of tumors and their potential transfer areas. Such operations often require highly specialized medical teams and advanced medical equipment to ensure their safety and effectiveness. The treatment uses high-energy rays for local exposure to tumours in order to kill cancer cells, but this approach may have some side effects, such as radio-eateritis. As a full-body treatment, chemotherapy is usually used for para-surgery to reduce the risk of relapse or for extended survival for late patients. Comprehensive treatment combines different treatment methods, such as surgery, treatment and chemotherapy, with a view to achieving optimal treatment.
The recommended chemotherapy programmes, such as the NCCN guide and the CSCO guide, vary according to the type and period of cuisine cancer. For local end-of-life or transferal oesophagus cancer, common chemotherapy programmes include platinum 5-fluorine (5-FU), which can effectively inhibit the growth and spread of cancer cells. The platinum is a widely used chemotherapy drug that can destroy the DNA of cancer cells and prevent their fragmentation and proliferation. The 5-FU, on the other hand, is an anti- metabolic drug that can disrupt the DNA synthesis of cancer cells and thus inhibit their growth. Another option is the joint succultol platinum and 5-FU, a three-pharmaceutical joint programme that in some cases shows better efficacy. Visulfanol is a compound extracted from the plume of the Pacific Ocean, which prevents carcinogenic cell division by stabilizing micropipe proteins. In the case of edible gland cancer, chemotherapy programmes based on Osaliprip may be used, such as FOLFOX (Osaliprip, calcium folicate, 5-FU) or ECX (Stububi, Shunpa, Capitabin) which have proved their effectiveness in clinical trials. In addition, immunotherapy drugs, such as Pembroliizumab and Nivolumab, have been recommended for use against certain late-stage cuisine cancer patients, who attack cancer cells by activation of the human body ‘ s own immune system. The choice of treatment should take into account the specific circumstances of the patient, the biological characteristics of the tumor and the latest clinical test results to ensure that the patient has access to the most appropriate treatment for himself.
Doctors usually develop individualized treatment programmes based on the patient ‘ s overall state of health, the size of the tumor, its location, the extent of its spread and the age and history of the patient. During treatment, patient support and care are equally important, including nutritional support, pain management and psychological counselling, to help patients better respond to the challenges of treatment.
